Chronic Myelogenous Leukemia in Blastic Phase: A Model of Heterogeneity and Resistance in Acute Leukemia

Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ (1987) Chronic myelogenous leukemia in blast crisis: an analysis of 242 patients. Am J Med 83: 445–454PubMedCrossRefGoogle Scholar

Collins SJ (1986) Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis. J Clin Invest 78: 1392–1396PubMedCrossRefGoogle Scholar

Andrews DF III, Collins SJ (1987) Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis. Leukemia 1: 718–724PubMedGoogle Scholar

Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V (1989) Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74: 2318–2324PubMedGoogle Scholar

Bar-Eli M, Ahuja H, Foti A, Sun X-Z, Cline MJ (1989) The P53 gene in blast crisis, other hematologic malignancies and solid tumors. Blood 74 [Suppl 1] 465Google Scholar

Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J, Deisseroth A (1990) Rearrangement and expression of p.53 in the chronic phase and blastic crisis of chronic myelogenous leukemia. Blood 75: 180–189PubMedGoogle Scholar

Zhang W, Del Giglio A, Kantarjian H,Talpaz M, Deisseroth A (1991) Nuclear p53 protein increases from normal levels inc hronic phase CML to high levels in peripheral blood cells of most blast crisis CML patients. Soc Clin Oncol (to be published)Google Scholar

Wetzler M, Kurzrock R, Estrov Z, Shtalrid M, Troutman K, Kantarjian H, Gutterman JU, Talpaz M (1990) Constitutive expression of interleukin-1 beta correlates with interfe-ron-alpha resistance in chronic myelogenous leukemia. Blood 76 [Suppl 1]: 335aGoogle Scholar

Everson MP, Brown CB, Lilly MB (1980) Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood 74: 1472–1476Google Scholar

Gualtieri RJ, Emanuel PD, Zuckerman KS, Martin G, Clark SC,Shadduck RK, Dracker RA, Akabutu J, Nitschke R, Hetherington ML, Dickerman JD, Hakami N, Castleberry RP (1989) Granulocyte-macrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia. Blood 74: 2360–2367Google Scholar

LeMaistre A, Lee MS, Talpaz M, Kantarjian HM, Freireich EJ, Deisseroth AB, Trujillo JM, Stass SA (1980) RAS oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 73: 889Google Scholar

Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ, Trujillo JM, Lee M-S, Stass SA (1990) RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76: 1214–1219PubMedGoogle Scholar

Padua RA, Carter G, Hughes D, Gow J, Farr C, Oscier D, McCormick F, Jacobs A (1988) RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 2: 503–510PubMedGoogle Scholar

Thomas ED, Clift RA, Fefer A, Appelbaum FR et al. (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155–163PubMedGoogle Scholar

Goldman JM, Apperley JF, Jones L, Marcus R et al. (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314: 202–207PubMedCrossRefGoogle Scholar

Haines LD, Goldman JM, Worsley AM, McCarthy DM et al. (1984) Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probably pro-longation of survival for some patients. Br J Haematol 58: 711–721PubMedCrossRefGoogle Scholar

Reiffers J, Gorin N, Michallet M, Maraninchi D, Herve P (1986) Autografting for chronic granulocytic leukemia in transformation. J Natl Cancer Inst 76: 1307–1310PubMedGoogle Scholar

Iacoboni SJ, Plunkett WK, Kantarjian H, Estey E, Keating MJ, McCredie KB, Freireich EJ (1986) High dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4: 1079–1088PubMedGoogle Scholar

Kantarjian H, Walters R, Keating M, Talpaz M, Andersson B, Beran M, Mcredie K, Freireich E (1988) Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62: 672–676PubMedCrossRefGoogle Scholar

DiRaimondo F, Milone G, Guglielmo P, Cacciola E, Giustoliso R (1985) Treatment of CML blast crisis with low dose ara-C. Br J Haematol 60: 773–774PubMedCrossRefGoogle Scholar

Koller CA, Miller DM (1986) Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med 315 (23): 1433–1438PubMedCrossRefGoogle Scholar

Koller C, Keating M, Walters R et al. (1988) Mithramycin and hydroxyurea in chronic myelogenous leukemia and other hematologic malignancies. Blood 72 [Suppl 1]: 209aGoogle Scholar

Trumper L, Lie JVD, Goudsmit R, Ho AD, Hunstein W (1988) Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea: a retrospective analysis. 22nd Congress of ISH, Milan, SYM-TU-6–6, 1988Google Scholar

Antimi M, Poeta GD, Cianciulli P, Scimo MT et al. (1988) Plicamycin and hydroxyurea in the treatment of blast phase and accelerated phase of the Ph’ chronic myelogenous leukemia. 22nd Congress of ISH, Milan, OPTU-6–6, 1988Google Scholar

Tricot G, Jayaram HN,Weber G, Hoffman R (1990) Tiazofurin: biological effects and clinical uses. Int J Cell Cloning 8: 161–170Google Scholar